Akari Therapeutics raises ~$5.5M via private placement of ADSs and warrants

Akari Therapeutics Plc

Gross proceeds of ~$5.5M from 1,470,588 ADSs at $3.74 per unit; three closings through July 15, 2026.
Each unit includes one ADS (or pre-funded warrant) plus Series H/I/J warrants exercisable at $3.74 per ADS.
Warrants require shareholder approval; pre-funded warrants exercisable immediately.
Net proceeds for working capital and general corporate purposes; Paulson Investment paid 2% cash fee plus 117,647 ADSs.
Offering exempt from registration under Section 4(a)(2) and Regulation D.

item 1.01 item 3.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-26-025037
form_type: 8-K
ticker: AKTX
cik: 0001541157
company_name: Akari Therapeutics Plc
filed_at: 2026-05-22T20:30:23+00:00
discovered_at: 2026-05-22T20:32:00.483960+00:00
generated_at: 2026-05-22T20:52:27.140000+00:00
sec_items: ["1.01", "3.02", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-26-025037
json_url: https://secwatch.observer/filing/0001493152-26-025037.json
markdown_url: https://secwatch.observer/filing/0001493152-26-025037.md
text_url: https://secwatch.observer/filing/0001493152-26-025037.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1541157/000149315226025037/0001493152-26-025037-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1541157/000149315226025037/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-26-025037

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.